The value of some genetic factors for prediction of chronic hepatitis C antiviral treatment effectiveness

Abstract

Aim: To determine the value of gene polymorphisms of interleukin-28B (IL28B), RNase L, HLA DRB1*1101 and HLADQB1*03 alleles as predictors of antiviral treatment efficacy in patients with chronic hepatitis C (CHC).Material and methods. A total of 156 in-patients with chronic hepatitis C (65.4% men, 62.4% had genotype 1 hepatitis C virus – HCV) were studied. The results of treatment with interferon (IFN) and ribavirin (RBV) were analyzed in 74 patients. Polymerase chain reaction identified single nucleotide polymorphisms (SNP) of the gene IL28B 39743165T>G (rs8099917), SNP 39738787C> T (rs12979860), RNase L gene (1385G>A), HLA DRB1*1101 and HLA-DQB1*03 alleles.Results. In patients with HCV genotype 1 mutant alleles were more common in SNP 39743165T>G (p=0.001) and 39738787C>T (p=0.0002) than in patients with other genotypes. Response to therapy IFN/RBV was higher in those with “favorable” TT variant (SNP 39743165T>G) and CC (SNP 39738787C>T), in those with their combination virologic response ffect were found according to genes IL28B and RNase L SNP variants, DRB1*1101 and HLA-DQB1*03 alleles.Conclusion. Testing for SNP 39738787C>T of IL28B gene is recommended before starting therapy IFN / RBV for all patients with genotype 1 HCV as a predictor of treatment response. Testing SNP 1385G>A gene RNase L and DRB1*1101, HLA-DQB1*03 alleles has no apparent prognostic value for patients with CHC antiviral therapy.

Keywords

• snp
• il28b
• rnase l
• hla-drb1*11
• hladqb1* 03
• chronic hepatitis c
• interferon therapy